TY - JOUR
T1 - Hepatitis B and C
AU - Karnsakul, Wikrom
AU - Schwarz, Kathleen B.
N1 - Funding Information:
Disclosure Statement: W. Karnsakul has had a relationship with Gilead as a sponsor for an open-label, multicenter, multicohort, single-arm study to investigate the safety and efficacy of sofosbuvir?plus?ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection and a phase 2, open-label, multicenter, multicohort study to investigate the safety and efficacy of ledipasvir/sofosbuvir fixed-dose combination in adolescents and children with chronic HCV-infection and a long-term follow-up registry for adolescent and pediatric subjects who received a Gilead hepatitis C virus direct-acting antiviral in chronic hepatitis C infection trials. K.B. Schwarz: Research grants from NIDDK, Gilead, BMS, and Roche; consulting for Gilead, Roche/Genentech, and Up to Date.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/6
Y1 - 2017/6
N2 - Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.
AB - Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.
KW - Direct-acting antiviral agents
KW - Hepatitis B
KW - Hepatitis C
KW - Pegylated interferon
KW - Spontaneous viral clearance
KW - Sustained virologic response
UR - http://www.scopus.com/inward/record.url?scp=85019210575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019210575&partnerID=8YFLogxK
U2 - 10.1016/j.pcl.2017.01.007
DO - 10.1016/j.pcl.2017.01.007
M3 - Review article
C2 - 28502443
AN - SCOPUS:85019210575
VL - 64
SP - 641
EP - 658
JO - Pediatric Clinics of North America
JF - Pediatric Clinics of North America
SN - 0031-3955
IS - 3
ER -